Can a Subcutaneous Shot of Monoclonal Antibodies Prevent COVID-19?

Postexposure prophylaxis with immunoglobulins has been the standard of care for many infectious diseases; thus, an effective immunoglobulin preparation for COVID-19 would provide a powerful new public health approach to controlling the current pandemic. Researchers conducted a manufacturer-supported placebo-controlled trial to assess the effectiveness of the REGEN-COV dual monoclonal antibody cocktail (casirivimab and imdevimab) given by subcutaneous injection as postexposure prophylaxis for symptomatic and asymptomatic COVID-19 in adolescent and adult household contacts of patients with the disease. Participants were randomized within 96 hours of COVID-19 diagnosis in the index patient. Analysis of these contacts was stratified by whether …